Generated September 5, 2026.
Overview
HLTH and VHT are both healthcare-focused equity ETFs, but they take fundamentally different approaches to the sector. HLTH is an actively managed fund that concentrates on companies applying artificial intelligence across healthcare workflows, from drug discovery to diagnostics and medical devices. VHT is a passively managed index tracker holding the broad MSCI US healthcare sector, weighted to limit single-stock concentration.
How they differ
The core distinction is active AI-focused selection versus broad passive indexing. HLTH picks companies specifically for AI application in healthcare; VHT holds the entire investable US healthcare market without thematic screening. This means HLTH's portfolio is likely much smaller and more concentrated around AI-driven narratives, while VHT's $19.4B in assets spreads exposure across hundreds of healthcare names—pharma, devices, diagnostics, insurers, and services.
Cost structure strongly favors VHT: its 0.09% expense ratio versus HLTH's 0.75% means passive indexing costs roughly one-tenth as much. On timeline, VHT has 22 years of track record since inception 01/26/2004; HLTH launched 07/21/2026 and is still establishing a performance history. VHT's $19.4B dwarfs HLTH's $7.66M, which raises potential liquidity and index-inclusion questions for the newer, much smaller fund.
Who each is best for
HLTH: Fits investors seeking concentrated exposure to an AI-in-healthcare narrative who have a longer time horizon and can tolerate concentrated portfolio risk in exchange for the possibility of outperformance if that thematic bet plays out.
VHT: Fits investors who want broad, low-cost healthcare sector exposure without thematic tilts—those prioritizing a diversified holding of established and emerging healthcare names with minimal fees and predictable quarterly income.
Key risks to know
- Concentration and thematic risk (HLTH). At $7.66M, HLTH is a micro-cap ETF with minimal assets under management. Its small size and focused AI-in-healthcare thesis create vulnerability both to fund closure if assets don't grow and to the risk that the AI healthcare narrative underperforms the broader sector, leaving shareholders concentrated in a crowded thematic bet.
- Active-manager performance risk (HLTH). Active selection on AI themes introduces manager risk; there is no guarantee the fund's stock-picking in a fast-moving sector will justify its 0.75% fee over time relative to broader healthcare or tech indexing.
- Sector cyclicality and regulatory exposure (both). Healthcare is sensitive to drug-pricing regulation, clinical trial outcomes, and patent expirations. Both funds carry that sector risk, but HLTH may be more vulnerable if AI-driven drug candidates or diagnostic tools face unexpected regulatory headwinds or setbacks that depress valuations.
- Liquidity risk (HLTH). At $7.66M, trading volume and bid-ask spreads may be wider than in VHT, making entry and exit more costly for retail investors, especially in volatile markets.
Bottom line
If you want broad, low-cost healthcare exposure with established liquidity and a modest yield, VHT's passive indexing and 0.09% fee structure stand out. If you believe AI application in healthcare is a multiyear secular trend worth concentrating on despite higher fees and fund immaturity, HLTH's thematic focus aligns with that conviction—but that bet comes with meaningful concentration and manager-selection risk. Past performance of either fund does not predict future results.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
